Victoria, BC – January 20, 2015 — Genologics today announced that GenomeDx Biosciences has implemented GenoLogics’ laboratory information management system, Clarity LIMS, to support whole transcriptome analysis workflows as part of their mission to address unmet clinical needs in the management of prostate cancer. Headquartered in Vancouver BC, GenomeDx will use Clarity LIMS in its CLIA-certified lab in San Diego, CA.
In the U.S. alone, there are an estimated 2.5 million men who are living with prostate cancer. An estimated 230,000 are diagnosed each year with over 100,000 undergoing surgery to treat their cancer. According to clinical risk assessment, nearly half of men should be considered for post-surgery radiation even though their cancer may not recur. Using their groundbreaking genomic test, the Decipher® Prostate Cancer Classifier, GenomeDx is able to predict the probability of cancer spread for men after surgery. Clinicians can then use this information, along with other clinical factors, to better guide postoperative treatment decisions and in certain men, avoid the side effects and high costs associated with treatment.
GenomeDx will use the cloud-based version of Clarity LIMS to support samples processed using the Decipher Test. Built specifically for genomics labs, Clarity LIMS provides end-to-end sample tracking, automation, preconfigured workflows, and superior usability. According to Andy Katz, PhD and Chief Operating Officer at GenomeDx, “We chose Clarity LIMS because it supports our laboratory quality assurance policies and it fits into our existing environment through use of the robust application programming interface (API).”
“We are happy to support GenomeDx and their transformational work to personalize treatment for cancer patients,” says Michael Ball, CEO of GenoLogics. “We look forward to working with them to optimize Clarity LIMS so they can continue to provide patients with actionable treatment information.”
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk-assessment tools. GenomeDx is based in San Diego, California, and Vancouver, British Columbia. To learn more, visit www.genomedx.com
GenoLogics develops the industry-leading laboratory information management system (LIMS) for life sciences organizations. Clarity LIMS helps labs gain efficiencies and throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations. Whether your lab is regulated or unregulated, big or small, Clarity LIMS will streamline your lab operations so that you can focus on advancing healthcare. Founded in 2002 and privately held, GenoLogics has offices in Canada, U.S., and Europe. www.genologics.com
GenoLogics Life Sciences Software